PHARMACOLOGY OF COGNITION IN SCHIZOTYPAL PERSONALITY
Mount Sinai School Of Medicine Of Cuny, New York NY
Investigators
Linked publications & trials
Abstract
While enormous strides have taken place in our understanding of schizophrenia, the interpretation of most studies of schizophrenic patients is complicated by the fact that chronic schizophrenia is an "end-stage" disease with evidence for generalized pathology in multiple brain systems, probably involving the convergence of a number of distinct etioligic factors. As a result, it may be difficult to disentangle the specific brain mechanisms involved in its pathogenesis. Schizotypal personality disorder (SPD) respresents a disorder clearly documented to be related to schizophrenia and is the most common phenotype for the genetic diathesis to the schizophrenia-related disorders. The specific major objectives of the proposal are to 1) identify and clinically diagnose 75 SPD patients, 75 other, non-schizophrenia related, personality disorder patients, and 75 normal control subjects over 5 years; 2) characterize their cognitive function in these domains, and 3) evaluate performance on these tasks in each cohort following a randomized double-blind placebo controlled administration of amphetamine (30 mg).
View original record on NIH RePORTER →